Journal: Scientific Reports
Article Title: Glypican-4 serum levels are associated with cognitive dysfunction and vascular risk factors in Parkinson’s disease
doi: 10.1038/s41598-024-54800-8
Figure Lengend Snippet: Glypican-4 levels in different biofluids and correlation with clinical parameters. ( A – C ) GPC-4 levels of PD patients and CTR in CSF ( A ), serum ( B ) and tear fluid ( C ). Mann–Whitney-U test, n.s., not significant. ( D – F ) Correlation analysis of GPC-4 levels and age of PD patients in CSF ( D ), serum ( E ) and tear fluid ( F ). ( G – I ) Correlation analysis of GPC-4 levels and MoCA score of PD patients in CSF ( G ), serum ( H ) and tear fluid ( I ). GPC-4, Glypican-4; PD, Parkinson’s disease; CTR, control subjects with similar age range; CSF, cerebrospinal fluid; TF, tear fluid; MoCA, Montreal cognitive assessment. r, Spearman’s Rho; ns, not significant. p < 0.05 was considered significant.
Article Snippet: To assess GPC-4 levels in CSF and blood serum of PD patients and CTR we used a commercial ELISA assay with highly specific human GPC-4 antibodies (#SEA998Hu, Cloud-Clone Corp., Katy, TX).
Techniques: MANN-WHITNEY